REVIEW
|
doi:10.20944/preprints202311.1632.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
checkpoint inhibitors; esophageal cancer; gastric cancer; immunotherapy; PD-L1; HER2; clinical trials; history; disparities
Online: 28 November 2023 (01:45:08 CET)